Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder
Authors:
- Michael R. LiebowitzMLMichael R. Liebowitz
- Jason CareriJCJason Careri
- Kyra BlattKBKyra Blatt
- Ann DraineADAnn Draine
- Junko MoritaJMJunko Morita
- Melissa MoranMMMelissa Moran
- Rita HanoverRHRita Hanover
Open Access
- 22 November 2017
- journal article
- research article
- Published by Wiley in Depression and Anxiety
- Vol. 34 (12) , 1164-1172
Abstract
Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD) are highly comorbid, yet the combined condition has not been subject to any placebo-controlled treatment trials. This study reports a trial of vortioxetine, an antidepressant that has also shown benefit in Generalized Anxiety Disorder (GAD), in patients meeting DSM-5 criteria for both MDD and SAD. The study was a 12-week double-blind, placebo-controlled comparison of vortioxetine 10–20 mg/day or placebo administered on a 1:1 ratio. The study was designed to include 40 male or female outpatients aged 18–70 years. The primary endpoint was the “composite” Clinical Global Impression of Improvement (CGI-I) responder rate, factoring in improvement in both MDD and SAD features. Major secondary outcome measures were changes on the Montgomery Asberg Depression Rating Scale (MADRS) and Liebowitz Social Anxiety Scale (LSAS). On the composite CGI-I, 10 of 20 (50%) vortioxetine and six of 20 (30%) placebo-treated patients were rated as responders, a non-significant difference. However, vortioxetine-treated patients did show significantly greater improvement than those on placebo on both the MADRS (effect size 0.672) and LSAS (effect size 0.714). Efficacy in depression was seen before improvement in SAD. Adverse effects were similar to those previously reported. In this preliminary trial vortioxetine appears safe and effective for patients with MDD comorbid with SAD, with robust effect sizes on dimensional measures of both depression and social anxiety, but failure to separate from placebo on the primary outcome measure of composite responder rate. More studies of patients with comorbid conditions are needed, as this mirrors what is often seen in clinical practice.Keywords
Funding Information
- Takeda Pharmaceuticals International Inc. and H. Lundbeck A/S
This publication has 18 references indexed in Scilit:
- A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptomsJournal of Affective Disorders, 2016
- Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual DysfunctionThe Journal of Sexual Medicine, 2015
- A randomized, double‐blind, fixed‐dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorderHuman Psychopharmacology: Clinical and Experimental, 2014
- A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorderInternational Journal Of Clinical Practice, 2013
- Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialEuropean Neuropsychopharmacology, 2012
- Incidence of Social Anxiety Disorder and the Consistent Risk for Secondary Depression in the First Three Decades of LifeArchives of General Psychiatry, 2007
- A Randomized Controlled Trial of Venlafaxine Extended Release in Generalized Social Anxiety DisorderThe Journal of Clinical Psychiatry, 2005
- Pharmacological treatment of social anxiety disorder: A meta-analysisDepression and Anxiety, 2003
- Social Phobia1987
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959